MiR-181d has an oncogenic function in CRC through increasing glycolysis, as well as the miR-181d/CRY2/FBXL3/c-MYC feedback loop may be a potential treatment for CRC patients. The gene discussed is FBXL3; the disease is colorectal carcinoma.